ES2142790T3 - Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada. - Google Patents
Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada.Info
- Publication number
- ES2142790T3 ES2142790T3 ES90909984T ES90909984T ES2142790T3 ES 2142790 T3 ES2142790 T3 ES 2142790T3 ES 90909984 T ES90909984 T ES 90909984T ES 90909984 T ES90909984 T ES 90909984T ES 2142790 T3 ES2142790 T3 ES 2142790T3
- Authority
- ES
- Spain
- Prior art keywords
- iga
- antigenic epitopes
- epitopes present
- membrane
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 239000012528 membrane Substances 0.000 title abstract 2
- 238000004873 anchoring Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000005204 segregation Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Abstract
EPITOPES ANTIGENICOS ASOCIADOS CON SEGMENTOS EXTRACELULARES DEL DOMINIO QUE ANCLA INMUNOBLOBULINAS A LA MEMBRANA DE LA CELULA B. ESTOS EPITOPES ESTAN PRESENTES EN LAS CELULAS B PORTADORAS PERO NO SEGREGADA, DE IGA, EN FORMA SOLUBLE DE IGA. LOS EPITOPES PUEDEN SER EXPLOTADOS PARA TERAPIA Y PROFILAXIS. POR EJEMPLO, LOS ANTICUERPOS ESPECIFICOS PARA LAS EPITOPES ASOCIADOS CON LOS PEPTIDOS DE ANCLAJE QUE COMPRENDEN UNA EPITOPE DE DOMINIO IGA PUEDEN SER UTILIZADOS PARA INCREMENTAR LA PRODUCCION SEGREGADORA DE IGA CON OBJETO DE TRATAR A PACIENTES CON ENFERMEDADES INFECCIOSAS Y ALERGICAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/369,479 US5079344A (en) | 1989-06-21 | 1989-06-21 | Antigenic epitopes present on membrane-bound but not secreted IgA |
US07/455,080 US5089603A (en) | 1989-06-21 | 1989-12-22 | Antigenic epitopes present on membrane-bound but not secreted iga |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2142790T3 true ES2142790T3 (es) | 2000-05-01 |
Family
ID=27004597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90909984T Expired - Lifetime ES2142790T3 (es) | 1989-06-21 | 1990-06-21 | Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada. |
Country Status (11)
Country | Link |
---|---|
US (2) | US5089603A (es) |
EP (1) | EP0478665B1 (es) |
JP (1) | JP2612512B2 (es) |
AT (1) | ATE189856T1 (es) |
AU (1) | AU645256B2 (es) |
CA (1) | CA2060666C (es) |
DE (1) | DE69033461T2 (es) |
DK (1) | DK0478665T3 (es) |
ES (1) | ES2142790T3 (es) |
SG (1) | SG52589A1 (es) |
WO (1) | WO1990015614A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362643A (en) * | 1989-06-21 | 1994-11-08 | Tanox Biosystems | Antibodies to epitopes present on membrane-bound but not secreted IGA |
US5514776A (en) * | 1987-12-31 | 1996-05-07 | Tanox Biosystems, Inc. | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface |
US5266477A (en) * | 1990-02-02 | 1993-11-30 | Pitman-Moore, Inc. | Monoclonal antibodies which differentiate between native and modified porcine somatotropins |
US20100267023A1 (en) * | 1992-09-24 | 2010-10-21 | Keygene N.V. | Selective restriction fragment amplification: fingerprinting |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
IT1315254B1 (it) * | 1999-11-05 | 2003-02-03 | Diesse Diagnostica Senese Spa | Metodo per la determinazione qualitativa e quantitativa di anticorpiumani di classe igc. |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
UA87453C2 (ru) * | 2003-02-01 | 2009-07-27 | Вайет | Применения фрагмента ав для лечения болезни альцгеймера |
TWI374893B (en) * | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP4764830B2 (ja) * | 2003-12-17 | 2011-09-07 | ワイス・エルエルシー | 免疫原性ペプチド担体コンジュゲートおよびその生産法 |
CN1934127B (zh) | 2003-12-17 | 2015-08-19 | 杨森阿尔茨海默氏症免疫治疗公司 | Αβ免疫原性肽载体-偶联物及其生产方法 |
JP2008523815A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
JP2008524247A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
CA2624081C (en) * | 2005-09-29 | 2014-09-16 | Medimmune, Inc. | Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
MX2009010092A (es) | 2007-03-22 | 2010-02-09 | Genentech Inc | Anticuerpos anti ige apoptoticos. |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
AU2008242648B2 (en) * | 2007-04-18 | 2013-09-12 | Janssen Alzheimer Immunotherapy | Prevention and treatment of cerebral amyloid angiopathy |
US20080283557A1 (en) * | 2007-05-17 | 2008-11-20 | Julianne Desautels | Spout for food stuff container |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010097012A1 (en) | 2009-02-25 | 2010-09-02 | Tsewen Chang | ANTI-CεmX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES |
CN104603150A (zh) | 2012-04-20 | 2015-05-06 | 中央研究院 | 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 |
JP6316966B2 (ja) * | 2013-12-05 | 2018-04-25 | アカデミア シニカAcademia Sinica | mIgA−Bリンパ球の溶解及びIgA生産の減少が可能な抗ヒトmIgA抗体 |
KR20200110302A (ko) | 2017-10-31 | 2020-09-23 | 원니스 바이오테크 컴퍼니 리미티드 | IgE-매개 알레르기성 질환들의 치료 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE230883C (es) * | ||||
US4636463A (en) * | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
JP2724625B2 (ja) * | 1987-12-31 | 1998-03-09 | タノックス・バイオシステムズ・インコーポレーテッド | IgE産出性Bリンパ球上の独特な抗原決定基 |
-
1989
- 1989-12-22 US US07/455,080 patent/US5089603A/en not_active Expired - Lifetime
-
1990
- 1990-06-21 AU AU58547/90A patent/AU645256B2/en not_active Ceased
- 1990-06-21 EP EP90909984A patent/EP0478665B1/en not_active Expired - Lifetime
- 1990-06-21 ES ES90909984T patent/ES2142790T3/es not_active Expired - Lifetime
- 1990-06-21 JP JP2509317A patent/JP2612512B2/ja not_active Expired - Fee Related
- 1990-06-21 DK DK90909984T patent/DK0478665T3/da active
- 1990-06-21 WO PCT/US1990/003532 patent/WO1990015614A1/en active IP Right Grant
- 1990-06-21 AT AT90909984T patent/ATE189856T1/de not_active IP Right Cessation
- 1990-06-21 CA CA002060666A patent/CA2060666C/en not_active Expired - Fee Related
- 1990-06-21 SG SG1996006485A patent/SG52589A1/en unknown
- 1990-06-21 DE DE69033461T patent/DE69033461T2/de not_active Expired - Fee Related
-
1991
- 1991-11-04 US US07/785,565 patent/US5866129A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5866129A (en) | 1999-02-02 |
EP0478665A1 (en) | 1992-04-08 |
WO1990015614A1 (en) | 1990-12-27 |
AU645256B2 (en) | 1994-01-13 |
JP2612512B2 (ja) | 1997-05-21 |
US5089603A (en) | 1992-02-18 |
SG52589A1 (en) | 1998-09-28 |
DE69033461D1 (de) | 2000-03-30 |
ATE189856T1 (de) | 2000-03-15 |
CA2060666A1 (en) | 1990-12-22 |
DE69033461T2 (de) | 2000-10-12 |
JPH04504424A (ja) | 1992-08-06 |
CA2060666C (en) | 2001-07-10 |
AU5854790A (en) | 1991-01-08 |
EP0478665A4 (en) | 1993-02-17 |
DK0478665T3 (da) | 2000-07-24 |
EP0478665B1 (en) | 2000-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2142790T3 (es) | Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada. | |
Pappas | The fine structure of the nuclear envelope of Amoeba proteus | |
ES2184769T3 (es) | Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas. | |
AR037223A1 (es) | Anticuerpos bloqueadores de cripto, composiciones que los comprenden, y metodos que los utilizan | |
ES2055785T3 (es) | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. | |
ES2107454T3 (es) | Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos. | |
ES2530769T3 (es) | Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno | |
SE9900519D0 (sv) | A method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof | |
ES2100174T3 (es) | Nuevos anticuerpos reactivos con carcinomas humanos. | |
DE69734605D1 (de) | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung | |
ES2126145T3 (es) | Redireccionamiento de anticuerpos. | |
ES2134197T3 (es) | Vacunas contra el virus del herpes simplex vp16. | |
ES2167544T3 (es) | Dioxidos de benzotiazina como antagonistas de la endotelina. | |
DE3854300D1 (de) | Lymphocyteninhibierung durch hla-peptide. | |
TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
DE69327529D1 (de) | Immunologisch mit HLA homologe HIV Protein Epitope | |
ES2061705T3 (es) | Procedimiento de obtencion de un preparado antigenico de toxoplasma gondii y sus aplicaciones diagnosticas y profilacticas. | |
AR217932A1 (es) | Procedimiento para preparar una fibra polimera de acrilonitrilo y la fibra resultante | |
ES2109314T3 (es) | Procedimiento de preparacion de alcoxi-silanos. | |
AR014647A1 (es) | Un polipeptido lipl32 de proteina de membrana externa leptoespiral, un polinucleotido aislado, un vector de expresion, una celula huesped, un metodopara producir dicho polipeptido lipl32, uso de dicho polipeptido para la manufactura de un medicamento, un anticuerpo, una composicion farmaceutica, | |
AR010568A1 (es) | Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori | |
MX9203574A (es) | Metodo biotecnologico para la produccion de peptidos antigenicos relacionados con el antigeno p asociado al melanoma, y para preparar vacunas que los contienen. | |
ES2061731T3 (es) | Procedimiento de extraccion de antigenos de membrana con propiedades inmunogenicas de celulas neoplasicas humanas y los productos asi obtenidos. | |
ECSP024410A (es) | Moduladores cilcicos fusionados de la funcion de receptores nucleares hormonales | |
ES2058240T3 (es) | Nuevos peptidos sinteticos inmunologicamente activos utiles para la preparacion de una vacuna antimalarica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 478665 Country of ref document: ES |